ALLELIC VARIANTS OF GPR50

The present invention provides isolated polynucleotides encoding a receptor gene called GPR50 having at least one polymorphic sites.It furthermore provides a method for analysing polimorphic sites in said receptor gene. Certain of these polynucleotides having a polymorphic site (allelic variants ) a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DUNBAR, DONALD ROBERT, THOMSON, ANNE MARGARET
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides isolated polynucleotides encoding a receptor gene called GPR50 having at least one polymorphic sites.It furthermore provides a method for analysing polimorphic sites in said receptor gene. Certain of these polynucleotides having a polymorphic site (allelic variants ) are found to be more prevalent in a population of patients with clinical Bipolar Depression compared to a control population. A method for the geneti c testing of Bipolar Depression is a further embodiment of the present invention. Furthermore, polynucleotides encompassing these polymorphic sites , the invariant distal or proximal to the polymorphic site localized polynucleotides as well as the polynucleotides encoding GPR50 are part of th e invention. The present invention also provides a recombinant cell line expressing these novel receptors at appropriate levels such that novel compounds active at these receptors may be identified for therapeutic use.